Although some clinical parameters, such as serum PSA levels and Gleason score, may provide some prognostic utility in the treatment settings, there are currently no definitive clinical methods that can reliably predict the responses to clinical therapies for PCa[5-9]. This evidence concerns the gene KLK3 and posterior cortical atrophy.